

INSERM will discuss nanoreservoirs technology for regenerative medicine

SMI Group reports: Nadia Jessel, Research Director, INSERM will be speaking at the SMI's Adaptive Designs in Clinical Trials event (18-19 April 2016, London)



LONDON, UNITED KINGDOM, February 7, 2016 /EINPresswire.com/ -- Recently, INSERM have reported an active nanostructured collagen implant reinforced with human stem cells for bone regeneration. In the group, they have reported a "smart hybrid materials equipped with nanoreservoirs of therapeutics and stem cells ". This unique nanotechnology strategy is used to

entrap, protect, and stabilize therapeutic agents into polymer coatings acting as nanoreservoirs enrobing nanofibers of implantable membranes. ([Nanomedicine](#) (Lond) 2015)

Nadia Jessel will be presenting on: "Smart and living implant equipped with active therapeutics and stem cells for regenerative nanomedicine" at the SMI's annual event. The presentation will include the following topics:



We have reported an active nanostructured collagen implant reinforced with human stem cells for bone regeneration-a "Smart Hybrid Materials Equipped with Nanoreservoirs of Therapeutics and stem cells"
L. KELLER, Q. WAGNER, P. SCHWINTE & N. BENKIRANE-JESSEL

- Nanoreservoirs technology for regenerative medicine
- Active and living implant for osteoarticular regenerative nanomedicine
- Bone and cartilage regeneration

Returning for its 8th year, the [Adaptive Designs in Clinical Trials](#) event will highlight an array of topics, including adaptive designs within the context of a development programme, Bayesian analysis in adaptive design, biomarker-driven trials, regulatory issues associated with adaptive design, and more. To see the full event programme please visit: www.adaptivedesigns.co.uk

Other confirmed speakers include:

- Fredrik Ohrn Statistical Science Director, AstraZeneca
- Loic Darchy, Head of Statistical Methodology Group, Sanofi R&D
- Alex Sverdlov, Associate Director of Biostatistics, EDM Serono
- Bo Huang, Director of Biostatistics, Pfizer USA
- Philip Hougaard, Vice President, Biometrics, Lundbeck A/S
- Giacomo Mordenti, Senior Director, Head of Biostatistics, Grunenthal
- Frank Fleischer, Team Leader Clinical Biostatistics, Boehringer-Ingelheim

In addition to the conference, the event will feature an interactive half-day post-conference workshops held on the 20th April 2016: Design, Analysis and Simulation of Adaptive Clinical Trials Using ADDPLAN (Led by ICON Clinical Research)

8th annual Adaptive Designs in Clinical Trials conference and exhibition
18th – 19th April 2016
London, UK
Contact e-mail: aserazetdinova@smi-online.co.uk
Contact number: +44 (0) 20 7827 6093
Event Website: www.adaptivedesigns.co.uk

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information

Anna Serazetdinova
SMi Group Ltd
+44702078276180
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.